Can Merck’s remigromig compete with anti-VEGF treatments after BRUNELLO results?
Merck's remigromig met BRUNELLO's vision endpoint, but higher retinal complication rates complicate its potential in diabetic macular edema.
Pharma & Biotech
Pharma & Biotech
Merck’s $3bn EyeBio bet clears first pivotal test as remigromig matches Lucentis
Merck & Co.’s remigromig matched ranibizumab on vision improvement in a pivotal diabetic macular edema trial, validating a novel Wnt-targeting approach while higher rates of proliferative diabetic retinopathy and vitreous hemorrhage leave an important safety question unresolved.